Clinical Trial Update: A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis [Phase 2]

View source ↗

Summary

A Phase 2 clinical study is evaluating ianalumab in participants with diffuse cutaneous systemic sclerosis, sponsored by Novartis, and currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis

Drugs mentioned

• Ianalumab (ianalumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Status: RECRUITING